Thus, significant metabolic changes, such as hypermetabolism, insulin resistance, hyperglycemia, accelerated lipolysis and albumin catabolism (e.g., fever, stress), decreased synthesis, or inadequate intake and abnormal distribution (e.g., capillary leakage) are likely to occur in patients with COVID-19, thereby resulting in an increase in lean body mass. This evidence concerns the gene ALB and COVID-19.